ELISA News and Research

RSS

SARS-CoV-2-specific T cell and antibody responses in healthcare workers that suffered from COVID-19 one year ago

Researchers have been investigating the immune response in previously infected healthcare workers after they receive these vaccines.

13 Dec 2021

Neutralizing antibody response against SARS-CoV-2 variants in health care workers pre- and post-vaccination

Researchers examined neutralizing antibody levels in 48 vaccinated health care workers against the major SARS-CoV-2 variants.

10 Dec 2021

Immune responses against SARS-CoV-2 Delta variant after BNT162b2 vaccination in people living with HIV

Researchers from Sorbonne Universite have been investigating the effect of the BNT162b2 mRNA vaccine on HIV-positive individuals.

9 Dec 2021

Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

Researchers have developed Nanocovax, a COVID-19 subunit vaccine based on recombinant protein technology to produce the extracellular (soluble) portion of the S protein of SARS-CoV-2.

9 Dec 2021

High quality products for cultured meat research

AMSBIO has announced a new range of kits, media and reagents to assist in the development of cultured meat products - an exciting new area of food technology.

From AMS Biotechnology 9 Dec 2021

Study shows SARS-CoV-2 transmission in Ireland before first official COVID-19 report

New study findings showed evidence of SARS-CoV-2 dissemination in Ireland prior to the identification of the first official COVID-19 case.

8 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

SARS-CoV-2 S2 immunization as a pan-coronavirus vaccine approach

A new mouse model suggests that prior HCoV-OC43 S immunity primes neutralising antibody responses to otherwise subimmunogenic SARS-CoV-2 S exposure as well as promotes S2-targeting antibody responses.

6 Dec 2021

SARS-CoV-2 virus-like particles elicit potent neutralizing antibody response in variant challenge

Researchers develop a virus-like particle for SARS-CoV-2 based on the co-expression of the spike, membrane, and envelope structural proteins.

6 Dec 2021

SARS-CoV-2 immune memory in mRNA vaccine recipients

Researchers measured SARS-CoV-2–specific antibody, memory B cell, and memory T cell responses in a group of healthy subjects who generated primary immune responses to two doses of mRNA vaccine compared to a group of SARS-CoV-2–recovered vaccines.

6 Dec 2021

Sino Biological Launches A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)

Sino Biological, Inc. (https://www.sinobiological.com; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus

From Sino Biological Inc. 6 Dec 2021

Equipment-free handheld microfluidic injection provides visible readout of SARS-CoV-2 detection

In this paper, a group of researchers from Harvard Medical School, McGill University, and Tianjin University describes an on-chip diagnostic technology for the direct detection of SARS-CoV-2 N protein in nasal samples that combines the advantages of hydrodynamic microfluidic filtration and sandwich immunoassay.

5 Dec 2021

Automate your sample pooling with INTEGRA’s efficient pipetting solutions

INTEGRA’s automated pipetting solutions are helping scientists meet the challenge of efficiently pooling potentially infectious samples prior to testing.

From INTEGRA Biosciences 3 Dec 2021

Researchers report antibody cocktails are promising candidate tools for controlling new SARS-CoV-2 variants

Researchers from Academia Sinica in Taiwan have been investigating new antibodies that could have strong effects against SARS-CoV-2 infection.

2 Dec 2021

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

In new studies, researchers concluded that licorice triterpenoids could be candidates for anti-SARS-CoV-2 drug developments.

2 Dec 2021

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Researchers employ a structure-guided approach for the development of a series of ACE2-Fc variants using human IgG1 or IgG3 backbone.

1 Dec 2021

Prior infection with SARS-CoV-2 continues to provide protection from reinfection

Researchers from the University of Michigan investigated the correlation between SARS-CoV-2 infection and the severity of reinfections.

30 Nov 2021

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

29 Nov 2021

Novel influenza vaccine candidate shows promise

Researchers investigate the potential value of a new vaccine candidate for the influenza virus.

29 Nov 2021

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

A recent research paper by scientists from Denmark reveals that circulating plasmacytoid dendritic cells may be a potential therapeutic target to maintain desired levels of an antiviral compound known as interferon, allowing for the mitigation of coronavirus disease (COVID-19) severity. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

28 Nov 2021

ELISA News and Research

SARS-CoV-2-specific T cell and antibody responses in healthcare workers that suffered from COVID-19 one year ago

Neutralizing antibody response against SARS-CoV-2 variants in health care workers pre- and post-vaccination

Immune responses against SARS-CoV-2 Delta variant after BNT162b2 vaccination in people living with HIV

Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

High quality products for cultured meat research

Study shows SARS-CoV-2 transmission in Ireland before first official COVID-19 report

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

SARS-CoV-2 S2 immunization as a pan-coronavirus vaccine approach

SARS-CoV-2 virus-like particles elicit potent neutralizing antibody response in variant challenge

SARS-CoV-2 immune memory in mRNA vaccine recipients

Sino Biological Launches A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)

Equipment-free handheld microfluidic injection provides visible readout of SARS-CoV-2 detection

Automate your sample pooling with INTEGRA’s efficient pipetting solutions

Researchers report antibody cocktails are promising candidate tools for controlling new SARS-CoV-2 variants

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Prior infection with SARS-CoV-2 continues to provide protection from reinfection

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

Novel influenza vaccine candidate shows promise

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News